MX2009009530A - Composiciones de acidos nucleicos cerrados bicatenarios. - Google Patents

Composiciones de acidos nucleicos cerrados bicatenarios.

Info

Publication number
MX2009009530A
MX2009009530A MX2009009530A MX2009009530A MX2009009530A MX 2009009530 A MX2009009530 A MX 2009009530A MX 2009009530 A MX2009009530 A MX 2009009530A MX 2009009530 A MX2009009530 A MX 2009009530A MX 2009009530 A MX2009009530 A MX 2009009530A
Authority
MX
Mexico
Prior art keywords
nucleic acid
double
locked nucleic
acid compositions
stranded locked
Prior art date
Application number
MX2009009530A
Other languages
English (en)
Inventor
Peter Emtage
Original Assignee
Nventa Biopharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nventa Biopharmaceuticals Corp filed Critical Nventa Biopharmaceuticals Corp
Publication of MX2009009530A publication Critical patent/MX2009009530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

Se proporcionan agentes inmunoestimuladores, incluyendo ácidos nucleicos que tienen uno o más de un nucleótido ce ácido nucleico cerrado (LNA). Los ácidos nucleicos pueden comprender además porciones CpG. Los ácidos nucleicos pueden ser bicatenarios, y pueden comprender dsRNA.
MX2009009530A 2007-03-07 2008-03-07 Composiciones de acidos nucleicos cerrados bicatenarios. MX2009009530A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90546107P 2007-03-07 2007-03-07
US95027107P 2007-07-17 2007-07-17
PCT/CA2008/000473 WO2008106803A1 (en) 2007-03-07 2008-03-07 Double-stranded locked nucleic acid compositions

Publications (1)

Publication Number Publication Date
MX2009009530A true MX2009009530A (es) 2010-05-19

Family

ID=39737757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009530A MX2009009530A (es) 2007-03-07 2008-03-07 Composiciones de acidos nucleicos cerrados bicatenarios.

Country Status (10)

Country Link
US (1) US20090041809A1 (es)
EP (1) EP2125853A1 (es)
JP (1) JP2010519915A (es)
KR (1) KR20100051041A (es)
CN (1) CN101687900A (es)
AU (1) AU2008222523A1 (es)
BR (1) BRPI0808442A2 (es)
CA (1) CA2680060A1 (es)
MX (1) MX2009009530A (es)
WO (1) WO2008106803A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
WO2009149470A1 (en) 2008-06-06 2009-12-10 Aurora Biofuels, Inc. Vcp-based vectors for algal cell transformation
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
SG10201801667YA (en) 2009-03-19 2018-03-28 Emd Millipore Corp Removal of microorganisms from fluid samples using nanofiber filtration media
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US9029137B2 (en) 2009-06-08 2015-05-12 Aurora Algae, Inc. ACP promoter
US8865468B2 (en) 2009-10-19 2014-10-21 Aurora Algae, Inc. Homologous recombination in an algal nuclear genome
US8809046B2 (en) 2011-04-28 2014-08-19 Aurora Algae, Inc. Algal elongases
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2011011463A2 (en) * 2009-07-20 2011-01-27 Aurora Biofuels, Inc. Manipulation of an alternative respiratory pathway in photo-autotrophs
CA2776386C (en) 2009-10-02 2018-02-27 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
US8846388B2 (en) * 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
WO2012027017A2 (en) * 2010-06-25 2012-03-01 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
ES2774949T3 (es) 2010-08-10 2020-07-23 Emd Millipore Corp Método para la eliminación de retrovirus
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2655612B1 (en) 2010-12-23 2017-07-19 Shell Internationale Research Maatschappij B.V. Gene disruptants producing fatty acyl-coa derivatives
WO2012097347A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US8722359B2 (en) 2011-01-21 2014-05-13 Aurora Algae, Inc. Genes for enhanced lipid metabolism for accumulation of lipids
KR101551298B1 (ko) 2011-04-01 2015-09-08 이엠디 밀리포어 코포레이션 나노섬유 함유 복합재료 구조
AU2012249377A1 (en) 2011-04-28 2013-11-14 Aurora Algae, Inc. Algal desaturases
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
US9157101B2 (en) * 2012-12-21 2015-10-13 Algenol Biotech LLC Cyanobacterium sp. for production of compounds
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
WO2016105483A1 (en) 2014-12-23 2016-06-30 Algenol Biotech LLC Methods for increasing the stability of production of compounds in microbial host cells
WO2016167871A1 (en) 2015-04-17 2016-10-20 Emd Millipore Corporation Method of purifying a biological materia of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US10138489B2 (en) 2016-10-20 2018-11-27 Algenol Biotech LLC Cyanobacterial strains capable of utilizing phosphite
EP3690030A4 (en) 2017-09-28 2021-06-23 Industry-Academic Cooperation Foundation, Yonsei University METHOD FOR MANUFACTURING MYELOID-DERIVED SUPPRESSOR CELLS, SUPPRESSOR CELLS MANUFACTURED FROM MYEOLID AND USES THEREOF
WO2019211492A1 (en) * 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
EP3935156A4 (en) 2019-03-07 2022-12-28 The Regents of The University of California CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE
BR112021026720A2 (pt) * 2019-07-02 2022-02-15 Na Vaccine Inst Rna heteroestruturado, dsrna homogêneo, composição farmacêutica, agente farmacêutico homogêneo e agente terapêutico para o câncer
US20230302158A1 (en) * 2020-08-14 2023-09-28 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
EP1474432A1 (en) * 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
AU2003248791A1 (en) * 2002-07-03 2005-11-09 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
EP1941058A4 (en) * 2005-10-27 2010-01-20 Rosetta Inpharmatics Llc AMPLIFICATION OF NUCLEIC ACIDS USING NON-RANDOM PRIMERS
JP2009513716A (ja) * 2005-11-01 2009-04-02 アルナイラム ファーマシューティカルズ インコーポレイテッド ＲＮＡｉによるインフルエンザウイルス複製の抑制

Also Published As

Publication number Publication date
KR20100051041A (ko) 2010-05-14
US20090041809A1 (en) 2009-02-12
WO2008106803A1 (en) 2008-09-12
EP2125853A1 (en) 2009-12-02
CN101687900A (zh) 2010-03-31
CA2680060A1 (en) 2008-09-12
JP2010519915A (ja) 2010-06-10
BRPI0808442A2 (pt) 2014-08-05
AU2008222523A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
MX2009009530A (es) Composiciones de acidos nucleicos cerrados bicatenarios.
WO2006002038A3 (en) Immunostimulatory oligonucleotide multimers
WO2008086381A3 (en) Isothermal dna amplification
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
WO2010048585A3 (en) Oligomeric compounds and methods
WO2008087561A8 (en) Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways
CR20140422A (es) Composiciones de enzima digestiva estable
WO2006086673A3 (en) Nucleotide compositions and uses thereof
IL205880A0 (en) Aminoglycoside analogs, compositions comprising the same and uses thereof
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
EP1941058A4 (en) AMPLIFICATION OF NUCLEIC ACIDS USING NON-RANDOM PRIMERS
WO2007062160A8 (en) Methods and compositions for sequencing a nucleic acid
WO2009147537A3 (en) Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
WO2007042554A3 (en) Methods and compositions for treating immune disorders
WO2007134181A3 (en) 5'-modified bicyclic nucleic acid analogs
IL190153A0 (en) Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
MX2010004109A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
WO2010054154A3 (en) Bifidobacteria crispr sequences
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
WO2018146557A3 (en) Long double-stranded rna for rna interference
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
MX2009012482A (es) Oligonucleotidos de clase a con potencia inmunoestimuladora.
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal